Search for 'an:"1082"'

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

By Rojas Laimito, Katerin | Sepúlveda Sánchez, Juan Manuel | Manso Sánchez, Luis | Pascual, Tomás | Ciruelos Gil, Eva María. Ecancermedicalscience, 2016 . 10:632. , Formato Vancouver: Laimito KR, Gámez Pozo A, Sepúlveda J, Manso L, López Vacas R, Pascual T et al. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience. 2016 Apr 11;10:632.

Place Hold on Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

By Ciruelos Gil, Eva María. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016 . 34(14):1601-10. , Formato Vancouver: Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 May 10;34(14):1601-10.

Place Hold on Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

The need for post-mastectomy radiotherapy in patients with IBC.

By Ruiz Ares, Gustavo | Ciruelos Gil, Eva María | Manso Sánchez, Luis. Nature reviews. Clinical oncology, 2015 . 12(6):370. , Formato Vancouver: Ares GR, Ciruelos E, Manso L. The need for post-mastectomy radiotherapy in patients with IBC. Nat Rev Clin Oncol. 2015 Jun;12(6):370.

Place Hold on The need for post-mastectomy radiotherapy in patients with IBC.

SEOM clinical guidelines in early-stage breast cancer 2015.

By Ciruelos Gil, Eva María. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):939-45. , Formato Vancouver: García Sáenz JA, Bermejo B, Estevez LG, Palomo AG, González Farre X, Margeli M et al. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):939-45.

Place Hold on SEOM clinical guidelines in early-stage breast cancer 2015.

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

By Ciruelos Gil, Eva María. Breast cancer research and treatment, 2015 . 149(1):151-61. , Formato Vancouver: Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):151-61.

Place Hold on Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

By Ciruelos Gil, Eva María. The New England journal of medicine, 2015 . 372(8):724-34. , Formato Vancouver: Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34.

Place Hold on Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

By Manso Sánchez, Luis | Ciruelos Gil, Eva María. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(2):160-6. , Formato Vancouver: Salvador J, Manso L, De la Haba J, Jaén A, Ciruelos E, De Villena MC et al. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol. 2015 Feb;17(2):160-6.

Place Hold on Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

By Ciruelos Gil, Eva María. Cancer research, 2015 . 75(11):2243-53. , Formato Vancouver: Gámez Pozo A, Berges Soria J, Arevalillo JM, Nanni P, López Vacas R, Navarro H et al. Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. Cancer Res. 2015 Jun 1;75(11):2243-53.

Place Hold on Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

By Ciruelos Gil, Eva María. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 . 33(14):1564-73. , Formato Vancouver: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R et al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2015 May 10;33(14):1564-73.

Place Hold on CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

By Ciruelos Gil, Eva María. The Lancet. Oncology, 2015 . 16(16):1700-10. , Formato Vancouver: Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015 Dec;16(16):1700-10.

Place Hold on Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Adjuvant ovarian suppression in premenopausal breast cancer.

By Ciruelos Gil, Eva María. The New England journal of medicine, 2015 . 372(5):436-46. , Formato Vancouver: Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M et al; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436-46.

Place Hold on Adjuvant ovarian suppression in premenopausal breast cancer.

Trastuzumab in small tumours and in elderly women.

By Ciruelos Gil, Eva María. Cancer treatment reviews, 2014 . 40(1):41-7. , Formato Vancouver: Albanell J, Ciruelos EM, Lluch A, Muñoz M, Rodríguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014 Feb;40(1):41-7.

Place Hold on Trastuzumab in small tumours and in elderly women.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

By Ciruelos Gil, Eva María | Pascual Martínez, Pascual | Arroyo Vozmediano, María Luisa | Blanco Guerrero, Marta | Manso Sánchez, Luis | Parrilla Rubio, Lucía | Muñoz, César | Vega Alonso, Estela | Calderón, Monica Jackelin | Sancho, Blanca | Cortés-Funes Castro, Hernán. The Breast : official journal of the European Society of Mastology, 2014 . 23(3):201-8. , Formato Vancouver: Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014 Jun;23(3):201-8.

Place Hold on The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

By Manso Sánchez, Luis | Mendiola Fernández, César | Ciruelos Gil, Eva María. PLoS One, 2014 . 9(10):e109611. , Formato Vancouver: Gámez Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López Vacas R et al. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy. PLoS One. 2014 Oct 20;9(10):e109611.

Place Hold on The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

By Ciruelos Gil, Eva María. Cancer treatment reviews, 2014 . 40(7):862-71. , Formato Vancouver: Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014 Aug;40(7):862-71.

Place Hold on Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

European inter-institutional impact study of MammaPrint.

By Ciruelos Gil, Eva María. Breast (Edinburgh, Scotland), 2014 . 23(4):423-8. , Formato Vancouver: Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E et al. European inter-institutional impact study of MammaPrint. Breast. 2014 Aug;23(4):423-8.

Place Hold on European inter-institutional impact study of MammaPrint.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

By Ciruelos Gil, Eva María. The Lancet. Oncology, 2014 . 15(11):1269-78. , Formato Vancouver: Von Minckwitz G, Puglisi F, Cortés J, Vrdoljak E, Marschner N, Zielinski C et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78.

Place Hold on Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

By Ciruelos Gil, Eva María. The New England journal of medicine, 2014 . 371(2):107-18. , Formato Vancouver: Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I et al. International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18.

Place Hold on Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Dorta Suárez, Myriam | Ghanem Cañete, Ismael | Manneh Kopp, Ray | Manso Sánchez, Luis | Mendiola Fernández, César | Sepúlveda Sánchez, Juan Manuel | Valdiviezo N, | Vega Alonso, Estela. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013 . 15(6):467-71. , Formato Vancouver: Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin Transl Oncol. 2013 Jun;15(6):467-71.

Place Hold on Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

By Ciruelos Gil, Eva María. Lancet Oncology, 2013 . 14(6):461-71. , Formato Vancouver: Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71.

Place Hold on Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Shotgun proteomics of archival triple-negative breast cancer samples.

By Ciruelos Gil, Eva María. Proteomics Clinical Applications, 2013 . 7(3-4):283-91. , Formato Vancouver: Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E et al. Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl. 2013 Apr;7(3-4):283-91.

Place Hold on Shotgun proteomics of archival triple-negative breast cancer samples.

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013.

By Ciruelos Gil, Eva María. Clinical & Translational Oncology, 2013 . 15(12):1011-7. , Formato Vancouver: Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A. SEOM. SEOM clinical guidelines for the systemic treatment of early breast cancer 2013. Clin Transl Oncol. 2013 Dec;15(12):1011-7.

Place Hold on SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013.

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Ghanem Cañete, Ismael | Manso Sánchez, Luis. Anti-Cancer Drugs, 2013 . 24(8):769-80. , Formato Vancouver: Ciruelos E, Cortés-Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs. 2013 Sep;24(8):769-80.

Place Hold on Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

By Ciruelos Gil, Eva María. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2013 . 31(20):2586-92. , Formato Vancouver: Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013 Jul 10;31(20):2586-92.

Place Hold on Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

By Ciruelos Gil, Eva María. Expert review of pharmacoeconomics & outcomes research, 2013 . 13(3):381-91. , Formato Vancouver: Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M et al. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):381-91.

Place Hold on Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

Neoadyuvancia en cáncer de mama

By Ciruelos Gil, Eva María. Madrid: Fundación para la Investigación y Formación en Oncología, 2012 . p. 17-19 , Formato Vancouver: Ciruelos E. Neoadyuvancia en cáncer de mama. En: Cortés-Funes H, coord. XXIV Curso Avanzado de la Oncología Médica, 20-23/junio/2012: San Lorenzo de El Escorial (Madrid). Madrid: Fundación para la Investigación y Formación en Oncología; 2012. p. 17-19.

Place Hold on Neoadyuvancia en cáncer de mama

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Paz-Ares Rodríguez, Luis. Investigational New Drugs, 2012 . 30(2):729-40. , Formato Vancouver: Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr;30(2):729-40.

Place Hold on Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

The present and future of gene profiling in breast cancer.

By Castañeda Altamirano, Carlos | Ciruelos Gil, Eva María. Cancer Metastasis Reviews, 2012 . 31(1-2):41-6. , Formato Vancouver: Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castañeda CA, Ciruelos E, et al. The present and future of gene profiling in breast cancer. Cancer Metastasis Rev. 2012 Jun;31(1-2):41-6.

Place Hold on The present and future of gene profiling in breast cancer.

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Paz-Ares Rodríguez, Luis. Medical Oncology, 2012 . 29(3):2240-50. , Formato Vancouver: Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, et al. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. Med Oncol. 2012 Sep;29(3):2240-50.

Place Hold on Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

By Ciruelos Gil, Eva María. Breast Cancer Research and Treatment, 2012 , Formato Vancouver: Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012 Apr;132(3):843-51.

Place Hold on Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

Behaviour of breast cancer molecular subtypes through tumour progression.

By Andrés Esteban, Eva | Barcena García, Carmen | Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán. Clinical & Translational Oncology, 2012 . 14(6):481-5. , Formato Vancouver: Castañeda CA, Andrés E, Barcena C, Gómez HL, Cortés-Funés H, Ciruelos E. Behaviour of breast cancer molecular subtypes through tumour progression. Clin Transl Oncol. 2012 Jun;14(6):481-5.

Place Hold on Behaviour of breast cancer molecular subtypes through tumour progression.

Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes.

By Ciruelos Gil, Eva María | Rodríguez Peralto, José Luis. PLoS ONE, 2012 . 7(8):e42494. , Formato Vancouver: Dueñas M, Santos M, Aranda JF, Bielza C, Martínez-Cruz AB, Lorz C, et al. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One. 2012;7(8):e42494.

Place Hold on Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes.

Anticuerpos monoclonales en el tratamiento del cáncer de mama

By Ciruelos Gil, Eva María. . p. 121-124 , Formato Vancouver: Ciruelos Gil E. Anticuerpos monoclonales en el tratamiento del cáncer de mama. En: Sociedad Española de Oncología Médica. Ponencias X Congreso Nacional SEOM: 23 al 25 de junio de 2005, Zaragoza, Auditorio-Palacio de Congresos. Zaragoza: SEOM; 2005. p. 121-4.

Place Hold on Anticuerpos monoclonales en el tratamiento del cáncer de mama

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

By Ciruelos Gil, Eva María. European Journal of Cancer, 2011 . 47(16):2387-2395. , Formato Vancouver: Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer. 2011;47(16):2387-95.

Place Hold on Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

Implication of miRNA in the diagnosis and treatment of breast cancer

By Castañeda Altamirano, Carlos | Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Agulló Ortuño, María Teresa. Expert Review of Anticancer Therapy, 2011 . 11(8):1265-1275. , Formato Vancouver: Castañeda CA, Agullo-Ortuño MT, Fresno Vara JA, Cortes-Funes H, Gomez HL, Ciruelos E. Implication of miRNA in the diagnosis and treatment of breast cancer. Expert Rev Anticancer Ther. 2011 Aug;11(8):1265-75.

Place Hold on Implication of miRNA in the diagnosis and treatment of breast cancer

Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors

By Castellano, Daniel | Hitt Sabag, Ricardo | Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Hitt Sabag, Ricardo | Colomer, R.. Annals of Oncology, 2003 . 14(5):783-787 , Formato Vancouver: Castellano D, Hitt R, Ciruelos E, Cortés-Funes H, Colomer R. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003 May;14(5):783-7.

Place Hold on Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors

Tratamiento adyuvante de las metástasis resecadas

By Grávalos Castro, Cristina | Ciruelos Gil, Eva María | Martínez Pueyo, José Ignacio | Gómez Martín, Carlos. . p. 181-196. , Formato Vancouver: Grávalos Castro C, Ciruelos Gil E, Martínez Pueyo JI, Gómez Martín C. Tratamiento adyuvantye de las metástasis resecadas. En: Díaz-Rubio E, coordinador. Cáncer colorrectal. Madrid: Ergon; 2000. p. 181-96.

Place Hold on Tratamiento adyuvante de las metástasis resecadas